NASDAQ:PTIX Protagenic Therapeutics (PTIX) Stock Price, News & Analysis → The Military's $700M 'AI Software Bullet' (From Behind the Markets) (Ad) Free PTIX Stock Alerts $1.03 +0.09 (+8.95%) (As of 11:56 AM ET) Add Compare Share Share Today's Range$1.01▼$1.1350-Day Range$0.90▼$1.8052-Week Range$0.68▼$2.22Volume58,287 shsAverage Volume12,272 shsMarket Capitalization$4.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get Protagenic Therapeutics alerts: Email Address Ad Behind the MarketsThe Military's $700M "AI Software Bullet"The Pentagon is spending over $700 MILLION on a top-secret project called "Overmatch." It's a software-defined networking solution that will connect all sensors, weapons, platforms, and personnel across our military branches.Get the name and stock ticker of this critical military tech firm HERE>>> About Protagenic Therapeutics Stock (NASDAQ:PTIX)Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Read More PTIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTIX Stock News HeadlinesMay 22, 2024 | finance.yahoo.comProtagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric DisordersApril 17, 2024 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston SummitJune 18, 2024 | Behind the Markets (Ad)Protect Your Bank Account from ChinaChina is set to launch a gold-backed currency that could shake the financial world. This move will give them unprecedented power over global finance. And could divert trillions from U.S. Treasury bonds.April 17, 2024 | finance.yahoo.comProtagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston SummitApril 2, 2024 | msn.comProtagenic Therapeutics, Inc. (NASDAQ:PTIX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comProtagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric DisordersMarch 25, 2024 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings CallFebruary 13, 2024 | finance.yahoo.comProtagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related DisordersJune 18, 2024 | Behind the Markets (Ad)Bigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ONE stock you should be watching.December 17, 2023 | morningstar.comProtagenic Therapeutics Inc PTIXNovember 14, 2023 | seekingalpha.comPTIX Protagenic Therapeutics, Inc.October 13, 2023 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics Announces Date of Annual Shareholder MeetingOctober 13, 2023 | finance.yahoo.comProtagenic Therapeutics Announces Date of Annual Shareholder MeetingSeptember 26, 2023 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114September 26, 2023 | finance.yahoo.comProtagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114June 17, 2023 | uk.finance.yahoo.comPTIX - Protagenic Therapeutics, Inc.March 24, 2023 | benzinga.comProtagenic Therapeutics Stock (NASDAQ:PTIX), DividendsMarch 22, 2023 | finanznachrichten.deProtagenic Therapeutics, Inc.: Protagenic Therapeutics to Effect 1-for-4 Reverse Stock SplitMarch 22, 2023 | finance.yahoo.comProtagenic Therapeutics to Effect 1-for-4 Reverse Stock SplitSeptember 7, 2022 | investing.comPTIX_old Historical DataAugust 12, 2022 | finance.yahoo.comProtagenic Therapeutics, Inc. (PTIX)April 26, 2022 | finance.yahoo.comProtagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27thJanuary 20, 2022 | nasdaq.comProtagenic Therapeutics, Inc. Common Stock (PTIX)November 16, 2021 | finance.yahoo.comProtagenic Therapeutics Announces Third Quarter 2021 Results and Business UpdateAugust 30, 2021 | finance.yahoo.comProtagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ETAugust 17, 2021 | finance.yahoo.comProtagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business UpdateJuly 23, 2021 | marketwatch.comProtagenic Therapeutics Updates on Patient Enrollment for PT00114 Trial, Shares LowerSee More Headlines Receive PTIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protagenic Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today6/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PTIX CUSIPN/A CIK1022899 Webwww.protagenic.com Phone212-994-8200Fax603-761-6223EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,000,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-156.36% Return on Assets-124.79% Debt Debt-to-Equity RatioN/A Current Ratio5.53 Quick Ratio5.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.83 per share Price / Book1.14Miscellaneous Outstanding Shares4,440,000Free Float2,794,000Market Cap$4.22 million OptionableNot Optionable Beta0.31 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Garo H. Armen Ph.D. (Age 71)Co-Founder & Executive Chairman of the Board Dr. Alexander Kenneth Arrow C.F.A. (Age 53)M.D., CFO & Secretary Comp: $150kDr. Andrew Slee (Age 74)Chief Operating Officer Dr. Robert Benjamin Stein M.D. (Age 73)Ph.D., Chief Medical Officer & Director Key CompetitorsPurple BiotechNASDAQ:PPBTGalectoNASDAQ:GLTOEdesa BiotechNASDAQ:EDSAMonopar TherapeuticsNASDAQ:MNPRFlora GrowthNASDAQ:FLGCView All CompetitorsInsidersAlexander K ArrowBought 8,000 shares on 10/12/2023Total: $6,480.00 ($0.81/share)View All Insider Transactions PTIX Stock Analysis - Frequently Asked Questions How have PTIX shares performed in 2024? Protagenic Therapeutics' stock was trading at $0.99 at the start of the year. Since then, PTIX stock has increased by 8.3% and is now trading at $1.0724. View the best growth stocks for 2024 here. Are investors shorting Protagenic Therapeutics? Protagenic Therapeutics saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 14,600 shares, an increase of 50.5% from the May 15th total of 9,700 shares. Based on an average trading volume of 15,300 shares, the days-to-cover ratio is currently 1.0 days. Approximately 0.4% of the company's stock are short sold. View Protagenic Therapeutics' Short Interest. When is Protagenic Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 24th 2024. View our PTIX earnings forecast. How were Protagenic Therapeutics' earnings last quarter? Protagenic Therapeutics, Inc. (NASDAQ:PTIX) issued its earnings results on Monday, April, 1st. The company reported ($0.38) earnings per share for the quarter. How do I buy shares of Protagenic Therapeutics? Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PTIX) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
